Kinase News and Research

RSS

CIP2A pathway involved in erlotinib response

Researchers have identified a novel mechanism, involving the cancerous inhibitor of protein phosphatase 2A pathway, which mediates the anti-tumour effects of erlotinib in non-small-cell lung cancer cells without epidermal growth factor receptor mutations.

16 Jul 2014

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel Pharmaceuticals, Inc. today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura).

16 Jul 2014

Neuroprotective effects of ginsenoside Rb1 on hippocampal neuronal injury, neurite outgrowth

The main pathological changes of Alzheimer's disease (AD) include amyloid-beta protein-induced hippocampal neuronal injury and neurite outgrowth impairment.

15 Jul 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson today announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013. Operational results increased 9.4% and the negative impact of currency was 0.3%.

15 Jul 2014

New potential avenues to predict and prevent ovarian cancer metastasis

Circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where it can grow and metastasize to other organs, scientists at The University of Texas MD Anderson Cancer Center report in Cancer Cell.

15 Jul 2014

Astrocytes play role in forming inhibitory synapses

Rio de Janeiro, Brazil- In the brains of all vertebrates, information is transmitted through synapses, a mechanism that allows an electric or chemical signal to be passed from one brain cell to another.

11 Jul 2014

New chemical compound protects against blindness and diabetes in animals

In a new study led by UC San Francisco scientists, a chemical compound designed to precisely target part of a crucial cellular quality-control network provided significant protection, in rats and mice, against degenerative forms of blindness and diabetes.

11 Jul 2014

Research uncovers how complex protein pivotal in cancer development is activated

New research has uncovered how a complex protein pivotal in the development of cancer, viral infection and autoimmune diseases is activated.

10 Jul 2014

Neuroprotective effects of lithium are likely related to gene expressions

Lithium, as a neuroprotective agent, benefits for neuronal survival. Recent cDNA array studies have demonstrated that mood stabilizer lithium exhibits neuroprotective effects through multiple targets.

9 Jul 2014

Scientists find a new strategy for brain cancer treatment

Scientists at the Montreal Neurological Institute and Hospital, McGill University and McGill University Health Centre have shown that a member of the protein family known as SUMO (small ubiquitin-like modifier) is a key to why tumour cells multiply uncontrollably, especially in the case of glioblastoma. T

9 Jul 2014

New mechanism of chemotherapy resistance in triple-negative inflammatory breast cancer

Researchers at Roswell Park Cancer Institute (RPCI) have identified a mechanism of breast cancer cells that leads to chemotherapy resistance in inflammatory breast cancer.

8 Jul 2014

CASI's ENMD-2076 gets FDA Orphan Drug designation for HCC treatment

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of hepatocellular carcinoma (HCC).

7 Jul 2014

$FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL$

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

7 Jul 2014

Thyroxine may overcome mutated thyroid hormone receptor effects

Patients with a mutation in the thyroid hormone receptor α gene that affects both the thyroid hormone receptor α1 and α2 protein variants have similar characteristics to patients with mutations affecting only the α1 variant, report researchers.

3 Jul 2014

Researchers use simple tactics to reduce unnecessary blood tests, health care spending

Researchers at Johns Hopkins Bayview Medical Center used two relatively simple tactics to significantly reduce the number of unnecessary blood tests to assess symptoms of heart attack and chest pain and to achieve a large decrease in patient charges.

2 Jul 2014

Partial nephrectomy predicts survival among metastatic RCC patients

Cytoreductive nephrectomy predicts improved survival among patients with metastatic renal cell carcinoma and synchronous metastases who have received first-line treatment with sunitinib, indicate study findings.

1 Jul 2014

Genetic variants alter chance of sunitinib dose reduction

Scientists have identified genetic variants that reduce the likelihood of sunitinib dose reduction in patients with metastatic renal cell carcinoma.

30 Jun 2014

18F-FGD-PET measures predict mRCC TKI response

Positron emission tomography could be used to predict the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy within a couple of weeks of a patient beginning treatment, research suggests.

30 Jun 2014

Biologists develop new method to investigate cell surface's organization on nanometer scale

After a ten-year effort, Prof. Dr. Michael Reth from the Institute of Biology III of the University of Freiburg and the Max Planck Institute of Immunobiology and Epigenetics has developed a method to investigate the cell surface's organization on a nanometer scale.

26 Jun 2014

Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

Erlotinib can be intercalated with the anti-tubule agent eribulin mesylate for patients with advanced non-small-cell lung cancer but it is unlikely to increase treatment efficacy in those without epidermal growth factor receptor activating mutations, research suggests.

25 Jun 2014